成人自身免疫性脑炎急性期免疫治疗的有效性与安全性:一项系统评价与网状Meta分析。
完整摘要 · 中文译文
背景:自身免疫性脑炎(AE)是一种免疫介导的中枢神经系统炎性疾病,伴有较高的致残率。急性期免疫治疗对于改善预后至关重要,然而现有方案的比较疗效和安全性仍不明确。因此,我们开展了一项贝叶斯网络荟萃分析,以比较AE的急性期免疫治疗策略。 方法:检索PubMed、Embase、Web of Science和Cochrane Library自建库至2025年10月收录的评估AE急性期免疫治疗的研究。采用贝叶斯网络荟萃分析。主要结局为治疗后改良Rankin量表(mRS)的变化;不良事件为次要结局。效应以均数差(MD)和风险比(RR)及95%可信区间(CrI)表示。采用累积排序曲线下面积(SUCRA)对干预措施进行排序。 结果:共纳入11项研究(1,359例患者),评估了七种策略:静脉注射甲泼尼龙(IVMP)、静脉注射免疫球蛋白(IVIG)、IVMP+IVIG、IVMP+血浆置换(PE)、IVMP+IVIG+PE、IVMP+免疫吸附(IA)和IVMP+艾加莫德(EFG)。在疗效方面,IVMP+EFG在纳入方案中mRS改善排名最高(MD = -0.99,95% CrI -1.30至-0.68;SUCRA = 95%),其次为IVMP+IA(MD = -0.87;SUCRA = 88%)。IVMP+PE排名最低(MD = 0.32;SUCRA = 0.2%)。在安全性方面,IVIG单药治疗的不良事件风险最低(RR = 0.51,95% CrI 0.24至0.97),而IVMP+PE风险最高(RR = 3.10,95% CrI 0.92 至9.60)。 结论:AE的急性期免疫治疗应根据疾病严重程度和抗体亚型进行个体化。在抗NMDAR亚组中,以及在基线mRS≥3的亚组中分别观察到一致的方向性结果。IVMP+EFG和IVMP+IA在短期功能改善方面排名较优,尽管证据主要基于观察性研究和小样本量。鉴于IVIG具有良好的安全性特征,其仍是一个合理的选择。 系统评价注册:https://www.crd.york.ac.uk/PROSPERO/view/CRD420251085606,注册号CRD420251085606。
完整摘要 · 英文原文
BACKGROUND: Autoimmune encephalitis (AE) is an immune-mediated inflammatory disorder of the central nervous system associated with substantial morbidity. Acute-phase immunotherapy is crucial for improving outcomes, yet the comparative efficacy and safety of available regimens remain unclear. We therefore performed a Bayesian network meta-analysis to compare acute-phase immunotherapeutic strategies for AE. METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to October 2025 for studies evaluating acute-phase immunotherapy in AE. A Bayesian network meta-analysis was conducted. The primary outcome was change in the modified Rankin Scale (mRS) after treatment; adverse events were secondary outcomes. Effects were expressed as mean differences (MD) and risk ratios (RRs) with 95% credible intervals (CrIs). The surface under the cumulative ranking curve (SUCRA) was used to rank interventions. RESULTS: Eleven studies (1,359 patients) were included, evaluating seven strategies: intravenous methylprednisolone (IVMP), intravenous immunoglobulin (IVIG), IVMP+IVIG, IVMP+plasma exchange (PE), IVMP+IVIG+PE, IVMP+immunoadsorption (IA), and IVMP+efgartigimod (EFG). For efficacy, IVMP+EFG ranked highest in mRS improvement among the included regimens (MD = -0.99, 95% CrI -1.30 to -0.68; SUCRA = 95%), followed by IVMP+IA (MD = -0.87; SUCRA = 88%). IVMP+PE ranked lowest (MD = 0.32; SUCRA = 0.2%). For safety, IVIG monotherapy had the lowest adverse-event risk (RR = 0.51, 95% CrI 0.24 to 0.97), whereas IVMP+PE had the highest risk (RR = 3.10, 95% CrI 0.92 to 9.60). CONCLUSION: Acute-phase immunotherapy for AE should be individualized by disease severity and antibody subtype. Consistent directional findings were observed in the anti-NMDAR subgroup and, separately, in the subgroup with baseline mRS ≥3. IVMP+EFG and IVMP+IA ranked favorably for short-term functional improvement, although the evidence was based mainly on observational studies and small sample sizes. IVIG remained a reasonable option given its favorable safety profile. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251085606, identifier CRD420251085606.